|1.||Jensen, Frances E: 5 articles (11/2013 - 06/2004)|
|2.||Rakhade, Sanjay N: 3 articles (11/2013 - 08/2008)|
|3.||Myhrer, Trond: 3 articles (12/2011 - 01/2010)|
|4.||Walker, David L: 2 articles (11/2014 - 03/2005)|
|5.||Davis, Michael: 2 articles (11/2014 - 03/2005)|
|6.||Aas, Pål: 2 articles (12/2011 - 01/2010)|
|7.||Enger, Siri: 2 articles (12/2011 - 01/2010)|
|8.||Richter, Angelika: 2 articles (06/2010 - 06/2007)|
|9.||Correa, Fernando M A: 2 articles (11/2009 - 05/2009)|
|10.||Crestani, Carlos C: 2 articles (11/2009 - 05/2009)|
11/01/2013 - "Brief NBQX administration during the 48 h postseizure in P10 Long-Evans rats suppresses transient mTOR pathway activation and attenuates spontaneous recurrent seizures, social preference deficits, and mossy fiber sprouting observed in vehicle-treated adult rats after early life seizures. "
11/01/2013 - "Although spontaneous recurrent seizures increased in adulthood in HS + V rats compared to controls (3.22 ± 1 seizures/h; p = 0.03), NBQX significantly attenuated later-life seizures (0.14 ± 0.1 seizures/h; p = 0.046). "
11/01/2013 - "Postseizure NBQX treatment significantly attenuated seizure-induced increases in p-p70S6K in the hippocampus (p < 0.01) and cortex (p < 0.001). "
12/08/2006 - "Lower dose of NBQX unexpectedly decreased thresholds for elicitation of spike-and-wave afterdischarges (ADs), clonic seizures accompanying this type of ADs and for transition into the second, limbic type of ADs. "
02/01/2005 - "However, focal delivery of NBQX to the seizure site reversibly reduced EEG and behavioral seizure activity without detectable side effects. "
01/01/1996 - "In the third study referred here, two groups of ischemic rats were given NBQX (30 mg/kg x 3) immediately after ischemia. "
03/01/1994 - "The objectives of this study were to evaluate the neuroprotective effects of NBQX initiated after focal cortical ischemia and to validate a method for measuring functional outcome in this model. "
08/01/2000 - "Gray matter damage and neuronal loss in the ventral horn were evident after ischemia, but no difference was noted between the saline and NBQX groups. "
08/01/1997 - "NBQX or thiokynurenic acid reduced, in a comparable manner, the effects of ischemia on the pigment epithelium, the photoreceptors, and the bipolar and the horizontal cells. "
02/01/1997 - "We found that administration of NBQX in generally accepted dosages can protect the rapidly dying SS neurons in hilus from only brief episodes of ischemia."
08/01/1996 - "The mechanical allodynia was only relieved by NBQX at a sedative dose. "
03/17/2000 - "By contrast, neither the D-AP5 nor the NBQX produced a statistically significant change in the thermal allodynia behavior in either forelimbs or hindlimbs in the hemisected group. "
09/20/2011 - "Thermal hyperalgesia induced by IL-1β (30pg) was completely prevented by the coadministration of CPP (3ng) but unaffected by NBQX (250ng). "
01/01/2004 - "When the same injection was given after L5 SNL-induced mechanical hyperalgesia had been established, MK-801 reversed the PWT reduction for 30-75 min, whereas NBQX, DL-AP3, or APDC had no effect. "
09/01/2003 - "Secondary mechanical hyperalgesia after gastrocnemius incision was dose-dependently blocked by NBQX but was only marginally affected by AP5 or MK-801. "
10/01/1993 - "Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke."
11/01/1993 - "Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model."
10/01/1993 - "The efficacy of delayed thrombolysis with recombinant tissue plasminogen activator was tested in combination with the ischaemic protecting drug NBQX in an embolic stroke model. "
01/01/1993 - "The cerebroprotective effect of NBQX in rats suggests a possible therapeutic role for non-N-methyl-D-aspartate antagonists given shortly after stroke onset."
03/01/1994 - "We tested the abilities of two potent non-N-methyl-D-aspartate (non-NMDA) glutamate antagonists [2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (NBQX)] and [1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazep ine hydrochloride (GYKI 52466)] to reduce neocortical infarction following 2 h of transient middle cerebral artery occlusion in a hypertensive stroke model in the rat and compared these effects against, and in combination with, a potent NMDA antagonist [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-amine maleate (MK-801)]. "
|5.||Spinal Cord Injuries (Spinal Cord Injury)
08/01/2002 - "NBQX treatment improves mitochondrial function and reduces oxidative events after spinal cord injury."
01/01/1999 - "Thus, the chronic effects of NBQX in reducing white matter loss after spinal cord injury appear to be attributable to the reduction of acute pathology and may be mediated through the protection of glia, particularly oligodendrocytes."
01/01/1999 - "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion."
10/18/2011 - "In conclusion, transplants of NRP/GRP combined with NBQX promote recovery of micturition function following spinal cord injury, likely through increased neuroprotection."
03/01/2000 - "We found that locally administered MK-801 or NBQX 15 min after spinal cord injury attenuated the amplitude, delayed the latency of sensory evoked potentials and increased the sensory conduction time across the injury site, but did not improve blood flow during the 4-h period of observation. "
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|2.||2,3- dioxo- 6- nitro- 7- sulfamoylbenzo(f)quinoxaline (NBQX)
|4.||AMPA Receptors (AMPA Receptor)
|6.||Kainic Acid (Kainate)
|7.||Excitatory Amino Acid Antagonists
|8.||Kainic Acid Receptors (Kainate Receptor)
|9.||Dizocilpine Maleate (Dizocilpine)
|10.||propionic acid (potassium propionate)